- Home
- FORA vs VSTM Comparison
FORA vs VSTM Comparison
Compare FORA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | VSTM |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | FORA | VSTM |
|---|---|---|
| Price | $2.11 | $7.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 29.6K | ★ 1.9M |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | $13,379,000.00 |
| Revenue This Year | $47.82 | $208.54 |
| Revenue Next Year | $10.11 | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | 33.79 |
| 52 Week Low | $1.64 | $3.46 |
| 52 Week High | $4.03 | $11.25 |
Technical Indicators
Market Signals| Indicator | FORA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 35.01 |
| Support Level | $2.04 | $7.59 |
| Resistance Level | $2.18 | $8.23 |
| Average True Range (ATR) | 0.05 | 0.55 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 43.75 | 9.00 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.